Seres Therapeutics

MCRB

Valor de mercado US$ 24,7 mi

Novel oral liquid formulation  of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”). The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres' board of directors in December 2022. The stock options have an exercise price of $5.72 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the individual's date of hire and as to 6.25% of the total number of shares subject to the option upon completion of each three full months of service to the Company thereafter.

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026.

Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) IST data support SER-155 as a potential treatment for irEC that may allow patients to continue cancer therapy; Company evaluating irEC clinical development strategy in consultation with KOLs Seres engaging potential partners, seeking capital to advance its SER-155 programs, including for the prevention of bloodstream infections in patients undergoing allo-HCT and those experiencing irEC Seres announces agreement to exit additional leased space early, further reducing ongoing facility-related cash costs, which follows announcement of balance sheet strengthening and facilities cost reduction transactions in June 2026 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported second quarter 2026 financial results and provided business updates.

Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer patients experiencing the gastrointestinal toxicity.

Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most participants achieving a steroid-free clinical response after treatment.

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript

80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) SER-155 has potential to treat irEC, a frequent side effect of immune checkpoint inhibitors (ICIs) that often causes halting of cancer treatment, without requiring treatment with systemic immunosuppressive drugs SER-155 was well tolerated, with no drug-related serious adverse events observed Drug pharmacology data provide confirmatory evidence of Seres' live biotherapeutics operating as designed to repair the mucosal epithelial barrier and reduce gastrointestinal inflammation, which supports possible expansion into multiple other inflammatory and immune diseases Company to host webcast today, July 8, at 8:30 am ET CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced encouraging top-line results from an IST evaluating SER-155 in patients with irEC.

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy.

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones